anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a medicine treating thyroid adenoma. The provided medicine is prepared after clinic test and repeated verification for many years and meets the traditional Chinese medicine theory. Traditional Chinese medicines are employed as raw materials, required components are separated after immersion, crushing, extraction and the like, and then agentia, tablets and capsules are prepared after compounding. Ecklonia kurome, cuttlebone, clam shell, alga, white poria, corallina officinalis, honeysuckle flower and aspongopus are employed as main materials and used for regulating qi, resolving depression, reducing phlegm and eliminating goiter. Radix scrophulariae, dutchmanspipe root, scutellaria baicalensis, rhizoma bolbostemmae, curcuma zedoary, radix curcumae, prunella vulgaris, Chinese arrowhead leaves, dioscorea bulbifera, white muscardine silkworm and dysosma pleiantha are employed as auxiliary materials and used for detoxifying, eliminating goiter, dispersing tumor, relieving pain and adjusting qi function. The provided medicine employs hardness softening , bind dissipating, swelling eliminating, urination promoting, tumor dispersing and pain relieving as treating principles, the whole body mechanism is conditioned, nidi are removed, principal and subordinate symptoms are treated simultaneously, therefore cachexia is improved, life quality is improved and life time is prolonged.
In this all study, participants will have the option to undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. The implantable loop recorder will be monitored at least once a week for up to 12 months.
This study utilized network pharmacology to investigate the effects of Xiaoyaosan (XYS) on the intervention of hyperplasia of mammary glands (HMG) by targeting specific genes and signaling pathways. The active ingredients and targets of XYS, which consisted of 8 traditional Chinese medicines (TCM), were identified using TCMSP. The gene targets associated with HMG were obtained from the GeneCards Database, and the intersection data between the 2 was integrated. Cytoscape 3.8.1 software was used to construct a network diagram illustrating the relationship between compounds, drug active ingredients, target proteins, and the disease. The protein-protein interaction network diagram was generated using STRING, and the core targets were analyzed. A total of 133 active ingredients in XYS and 7662 active ingredient targets were identified. Among them, 6088 targets were related to HMG, and 542 were common targets between the active ingredients and the disease. The protein-protein interaction (PPI) core network contained 15 targets, with 5 key targets playing a crucial role. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses have indicated that XYS has the potential to treat HMG by interfering with the AGE-RAGE signaling pathway in diabetic complications, the MAPK signaling pathway, and the PI3K-Akt signaling pathway. Additionally, molecular docking studies have shown excellent binding properties between the drug components and key targets. Thus, this study provides a theoretical foundation for a better understanding of the pharmacological mechanism and clinical application of XYS in the comprehensive treatment of HMG.
Ti workpiece surfaces to be ceramic coated are prevented with an antimony oxide-contg. skip and heated to 500-750 deg. C in an oxidising atmos. to produce an antimony-contg.  mixed oxide layer. The antimony oxide-contg. slip forms a paste or lacquer with water, alcohol, other low boiling point liquids or with organic liquids which are burnt off without residue at below 600 deg.C. USE/ADVANTAGE - In the enamelling of Ti surfaces. Process produces a durable, stable oxide intermediate layer which guarantees good bonding with the ceramic layer.
This was a prospective randomized multicentric study. After the screening visit, eligible subjects were randomly assigned to be explored by CE or PE (first line exploration). The alternative exploration was only performed if no diagnosis was evidenced by the examination assigned by randomization. An independent staff member assigned subjects in 1:1 ratio between CE and PE strategies with stratification for overt and occult bleeding and centers according to consecutive number that were kept in serialized sealed opaque envelopes. After the completion of these explorations, the patients returned at month 3, 6 and 12 thereafter. At each visit, clinical evaluation and laboratory tests were performed and patients were managed according to published recommendations2 (AGA medical position). The first line exploration as well as the alternative exploration could be done during the one year follow-up period only in case of severe relapse of OGIB or necessity to perform biopsies or a therapeutic procedure.
This invention relates to phytases, polynucleotides encoding them, uses o f the polynucleotides and polypeptides of the invention, as well as the prod uction and isolation of such polynucleotides and polypeptides. In particular , the invention provides polypeptides having phytase activity under high tem perature conditions, and phytases that retain activity after exposure to hig h temperatures. The phytases of the invention can be thermotolerant and/or t hermostable at low temperatures, in addition to higher temperatures. The phy tases of the invention can be used in foodstuffs to improve the feeding valu e of phytate rich ingredients. The phytases of the invention can be formulat ed as foods or feeds or supplements for either to, e.g., aid in the digestio n of phytate. The foods or feeds of the invention can be in the form of pell ets, liquids, powders and the like. In one aspect, phytases of the invention are stabile against thermal denaturation during pelleting; and this decreas es the cost of the phytase product while maintaining in vivo efficacy and de tection of activity in feed.
The efficacy of ALIQOPA was evaluated in a single-arm, multicenter, phase 2 clinical trial (NCT 01660451) CHRONOS-1 in a total of 142 subjects, which included 104 subjects with follicular B-cell non-Hodgkin lymphoma who had relapsed disease following at least two prior treatments. Patients must have received rituximab and an alkylating agent. Baseline patient characteristics are summarized in Table 5. The most common prior systemic therapies were chemotherapy in combination with anti-CD20 immunotherapy (89%), chemotherapy alone (41%), and anti-CD20 immunotherapy alone (37%). In CHRONOS-1, 34% of patients received two prior lines of therapy and 36% received three prior lines of therapy. 

*Refractory: No response or progression of disease within six months of last treatment.

One hundred forty-two patients received 60 mg ALIQOPA; 130 patients received fixed dose 60 mg ALIQOPA and 12 patients received 0.8 mg/kg equivalent ALIQOPA administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Treatment continued until disease progression or unacceptable toxicity. Tumor response was assessed according to the International Working Group response criteria for malignant lymphoma. Efficacy based on overall response rate (ORR) was assessed by an Independent Review Committee. Efficacy results from CHRONOS-1 are summarized in Table 6.

ORR = overall response rate; CI = confidence interval; CR = complete response;

PR = partial response; DOR = duration of response 

*Kaplan-Meier estimate 

The median time to response was 1.7 months (range 1.3 to 9.7 months).
Two randomized, active controlled trials of cIAI were performed. A double-blind trial was conducted primarily in North America to compare the efficacy of sequential oral moxifloxacin 400 mg once a day for 5 to 14 days to piperacillin/tazobactam followed by oral amoxicillin/clavulanic acid in the treatment of patients with cIAI, including peritonitis, abscesses, appendicitis with perforation, and bowel perforation. This study enrolled 681 patients, 379 of which were considered clinically evaluable. A second open-label international study compared moxifloxacin 400 mg once a day for 5 to 14 days to intravenous ceftriaxone plus intravenous metronidazole followed by oral amoxicillin/clavulanic acid in the treatment of patients with cIAI. This study enrolled 595 patients, 511 of which were considered clinically evaluable. The clinically evaluable population consisted of subjects with a surgically confirmed complicated infection, at least 5 days of treatment and a 25 to 50 day follow up assessment for patients at the Test of Cure visit. The overall clinical success rates in the clinically evaluable patients are shown in Table 16.   
Table 16: Clinical Success Rates in Patients with Complicated Intra-Abdominal Infections
In the present invention, an order information recording unit records order information for a patient. An arrival status recording unit records an arrival status indicating whether a patient has arrived or not, in association with an order for the patient. A receiving unit 40 receives patient identification information input to a portable terminal device 22. An order search unit 42 searches an order related to the patient identification information received by the receiving unit 40. When the arrival status associated with the order related to the patient identification information is indicating the patient's arrival, a determination processing unit 50 determines to display an input screen of medical interview information. In respond to the determination of the determination processing unit 50, a display processing unit 60 displays the input screen of the medical interview information on the portable terminal device 22.
Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention relates to a new method for successfully inducing the mutation of cell chemokine receptor CCR5 gene into CCR5Δ32 deletion gene by using the CRISPR-Cas9 genome editing technique. CCR5 is an important co-receptor for entry of Human Immunodeficiency Virus (HIV) into human host cells. CCR5Δ32 deletion is a 32-bp deletion in CCR5 coding region, which results in change and premature termination in the sequence following the 185th amino acid. Biallelic homozygous deletion of CCR5Δ32 is naturally resistant to HIV infection, i.e., the people carrying this mutation can't be infected by HIV. The present invention uses both lentiviral packaging system and the CRISPR technique to induce CCR5Δ32 deletion. Due to the characteristics of a wide range of Lentivirus infection, the invention can be applied to cells such as bone marrow stem cells and CD4+ T cells and can be expected to be the therapeutic drug for HIV/AIDS infection or other diseases.
Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
A composition comprising one or more lip interacting components, the lip interacting components (e.g. a sanshool, bungeanool, spilanthol, a capsaicinoid) having an ability to interact with one or more dermal receptors (e.g. those that interact with hydroxy-α-sanshool) in the lips of a user, the receptors having a role in the perception of, or change in, one or more of: temperature; touch/pressure; and pain; wherein in use, when the composition is applied to the lips of the user, the user notices a sensation in the lips, the sensation associated with the interaction of the receptors with the one or more lip interacting components. Preferably, the composition, when in use, causes at least two sensations (e.g. heat and fizzing) and may comprise two or more lip interacting components. The composition preferably comprises taste and smell components (e.g. an essential oil). Preferably, the composition comprising a dysgeusic component, which alters the perception of taste of the user. Also claimed are methods of weight loss comprising adding the composition described herein to the lips of a user between regular meals.
Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders, including severe constipation, or major GI tract surgery were not included in the Renvela clinical studies.

Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention. Consider using sevelamer suspension in patients with a history of swallowing disorders.

Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use [see Adverse Reactions (6.2)] . Inflammatory disorders may resolve upon Renvela discontinuation. Treatment with Renvela should be re-evaluated in patients who develop severe gastrointestinal symptoms.
PURPOSE: Ectopic fat accumulation plays a significant role in obesity-related metabolic dysfunction, and few studies have reported an association between ectopic gastric fat and metabolic risk factors. We aim to fulfill this need by assessing the degree of gastric submucosal fat accumulation in pathologic sections of 190 sleeve gastrectomy specimens.
METHODS: Study patients were divided into two groups (D1 and D2) based on whether fat accumulation exceeded 1/3 of the submucosa of the stomach. Demographic and metabolic risk factors were compared between the two groups. Metabolic risk variables that might be associated with the degree of fat accumulation were screened in the original cohort. After balancing for possible confounders, the robustness of the correlations was assessed using binary and conditional logistic regression analyses.
RESULTS: All study patients had fat accumulation in the submucosa of the stomach. C-reactive protein (CRP), body mass index (BMI), visceral fat area (VFA), and insulin resistance (IR) were higher in the D2 group than in the D1 group in the original cohort (P < 0.05). Logistic regression analysis showed that BMI and IR may be associated with increased fat accumulation. After balancing variables other than obesity indicators and IR using propensity score matching, BMI and IR remained significantly different between the two groups (P < 0.05). Further analysis of the matched cohort using two logistic regression analyses showed that IR was an independent risk factor for increased fat accumulation.
CONCLUSION: This study indicated that gastric submucosal fat accumulation was prevalent in patients with obesity and was associated with IR.
Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
PURPOSE:To obtain an F/0 type non-aqueous emulsified composition excellent in spreadability and stability with the elapse of time and enhanced in the lasting properties of effect by compounding a fluoropolymer having a perfluoroalkyl group and an alkyl group in its molecule, a liquid org. perfluoro-compound and an oily base material. CONSTITUTION:A fluoropolymer having a perfluoroalkyl group and an alkyl group in its molecule, a liquid org. perfluoro-compound and an oily base material are compounded to prepare a non-aqueous emulsified composition showing an org. perfluoro-compound in oil type dispersion state. The fluoropolymer has a perfluoroalkyl group and an alkyl group in its molecule. The org. perfluoro-compound is liquid at room temp. and, for example, perfluoroalkane or perfluoropolyether is designated. As the oily base material, oils and fats, wax, alcohol, higher fatty acid or silicone oil are designated.
The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysis through (1) engagement of immune effector cells, (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis.

As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Obinutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab. Obinutuzumab binds to FcγRIII using purified proteins with a higher affinity than rituximab. Obinutuzumab and rituximab bind with similar affinity to overlapping epitopes on CD20.
Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering "diet tips". This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes.
Drug: Gemcitabine hydrochloride and albumin binding paclitaxel 28 days is a cycle. On the 1st, 8th and 15th days of each cycle, 125 mg/m2 albumin binding paclitaxel will be administered intravenously，1000 mg/m2 gemcitabine hydrochloride will be administered immediately after the infusion of albumin binding paclitaxel.
PROBLEM TO BE SOLVED: To obtain a hemostatic agent capable of quickly and surely stopping the bleeding without necessitating an extensive surgical operation. SOLUTION: This hemostatic agent contains an ultrasonic sensitive agent such as porphyrin, chlorin, water-soluble chlorophyll derivative, acridine derivative, xanthene derivative, tetracycline, surfactant or mitomycin. The chlorin is phenophorbide or acrine derivative such as methylene blue, furosein, acrine orange or neutral red. The xanthene derivative is e.g. rhodamine, rose bengal or erythrocin. Tween 80 can be used as the surfactant. The ultrasonic sensitive agent is activated to coagulate the blood in a short time by introducing the ultrasonic sensitive agent to the bleeding site by intravenous injection and applying ultrasonic radiation to the bleeding site. Bleeding can easily and quickly be stopped by this process.
A double-blind, randomized, multi-center, placebo-controlled study was conducted to support the safety and efficacy of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets in the treatment of nausea and vomiting of pregnancy. Adult women 18 years of age or older and 7 to 14 weeks gestation (median 9 weeks of gestation) with nausea and vomiting of pregnancy were randomized to 14 days of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets or placebo. Two tablets of doxylamine succinate and pyridoxine hydrochloride were administered at bedtime on Day 1. If symptoms of nausea and vomiting persisted into the afternoon hours of Day 2, the woman was directed to take her usual dose of two tablets at bedtime that night and, beginning on Day 3, to take one tablet in the morning and two tablets at bedtime. Based upon assessment of remaining symptoms at her clinic visit on Day 4 (± 1 day), the woman may have been directed to take an additional tablet mid-afternoon. A maximum of four tablets (one in the morning, one in the mid-afternoon and two at bedtime) were taken daily. 

Over the treatment period, 19% of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets-treated patients remained on 2 tablets daily, 21% received 3 tablets daily, and 60% received 4 tablets daily. 

The primary efficacy endpoint was the change from baseline at Day 15 in the Pregnancy Unique-Quantification of Emesis (PUQE) score. The PUQE score incorporates the number of daily vomiting episodes, number of daily heaves, and length of daily nausea in hours, for an overall score of symptoms rated from 3 (no symptoms) to 15 (most severe). 

At baseline, the mean PUQE score was 9.0 in the doxylamine succinate and pyridoxine hydrochloride delayed-release tablets arm and 8.8 in the placebo arm. There was a 0.7 (95% confidence interval 0.2 to 1.2 with p-value 0.006) mean decrease (improvement in nausea and vomiting symptoms) from baseline in PUQE score at Day 15 with doxylamine succinate and pyridoxine hydrochloride delayed-release tablets compared to placebo (see Table 6).
FRUZAQLA 1 mg capsules contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

FRUZAQLA 1 mg contains FD&C Yellow No. 6 (sunset yellow FCF), which may cause allergic reactions.
The goal of this proposed study is to conduct a pilot trial of a web-based moral elevation intervention to determine if such an intervention is a feasible and acceptable therapeutic approach for Operations Enduring Freedom, Iraqi Freedom, and New Dawn Veterans with distress related to posttraumatic stress disorder (PTSD) and moral injury (MI). This study will also assess the feasibility of randomization, retention, and completion of a no-treatment condition (i.e., comparison group) in preparation for future randomized controlled trials (RCTs). The sample will include 24 Veterans (12 per group). The online intervention consists of two exercises per week for one month, totaling eight sessions. Sessions will include watching validated videos that elicit moral elevation and recalling moments when one experienced moral elevation in daily life, paired with journaling about one's reactions to witnessed virtuous behavior. Participants in the intervention condition will also be presented with a brief goal to be completed prior to the next session to facilitate greater social engagement. Participants randomized to the no-treatment condition will access the same online portal twice per week, but will not be exposed to any intervention components. All participants will complete brief self-report measures at each online session. All participants will also complete self-report measures at baseline and 1-month follow-up that will assess PTSD symptoms, MI distress, prosocial behavior, and quality of social relationships. At the follow-up assessment, participants randomized to the intervention condition will complete an individual qualitative interview with a member of the study team to assess acceptability and satisfaction with the intervention and proposed methodology, which will be coded and analyzed to inform future clinical trials. To supplement self-report measures, all participants will invite a significant other (e.g., spouse, close friend) to complete measures based on observations of the Veteran's behavior and social functioning at baseline and 1-month follow-up. Feasibility of recruitment, retention, and completion of the intervention will be analyzed by tracking the number of participants retained at each stage of the study, as well as the number of sessions completed in the intervention. Results from this study will be used to develop an RCT with a larger sample size to determine the efficacy of a moral elevation intervention and assess whether this novel approach leads to unique beneficial outcomes regarding PTSD and moral injury distress.